The advent of BCR-ABL tyrosine kinase inhibitors (TKIs) targeted therapy revolutionized the
treatment of chronic myeloid leukemia (CML) patients. Mitochondria are the key organelles …

The evolution of antitumor therapies has significantly improved cancer prognosis but has
concurrently resulted in cardiovascular toxicities. Understanding the biological mechanisms …

Development of tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL oncogene
constitutes an effective approach for the treatment of chronic myeloid leukemia (CML) and/or …

BACKGROUND: Mitochondrial dysfunction is a primary driver of cardiac contractile failure;
yet, the cross talk between mitochondrial energetics and signaling regulation remains …

In drug discovery, during the lead optimization and candidate characterization stages, novel
small molecules are frequently evaluated in a battery of in vitro pharmacology assays to …

Background Empagliflozin (EMPA), a selective sodium-glucose cotransporter type 2
(SGLT2) inhibitor, has been shown to reduce major adverse cardiovascular events in …

Deubiquitinases are a group of proteins that identify and digest monoubiquitin chains or
polyubiquitin chains attached to substrate proteins, preventing the substrate protein from …

This scholarly investigation presents pioneering drug candidates for combating leukemia,
distinguished by reduced side effects and elevated efficacy. The study focuses on azo …

Knowledge of the targets of therapeutic compounds is vital for understanding their action
mechanisms and side effects, but such valuable data is seldom available. The multiple …

The potential drug candidate novel Schiff base, 2-(((3-(4-methyl-1H-imidazol-1-yl)-5-
(trifluoromethyl) phenyl) imino) methyl) phenol (MITPIM) was synthesized by the reaction of …